An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2019
Price : $35 *
At a glance
- Drugs ASP 5878 (Primary)
- Indications Bladder cancer; Breast cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 30 Apr 2019 Results published in the Investigational New Drugs Journal.
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.